Last reviewed · How we verify
Multiple dose AZD2014
At a glance
| Generic name | Multiple dose AZD2014 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer (PHASE1)
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (PHASE1)
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (PHASE2)
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (PHASE2)
- AZD8186 First Time In Patient Ascending Dose Study (PHASE1)
- Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase (PHASE1)
- Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multiple dose AZD2014 CI brief — competitive landscape report
- Multiple dose AZD2014 updates RSS · CI watch RSS
- AstraZeneca portfolio CI